Meng‐Feng Tsai

2.4k total citations
57 papers, 1.9k citations indexed

About

Meng‐Feng Tsai is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Meng‐Feng Tsai has authored 57 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 16 papers in Molecular Biology. Recurrent topics in Meng‐Feng Tsai's work include Lung Cancer Treatments and Mutations (17 papers), Cancer Cells and Metastasis (6 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Meng‐Feng Tsai is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Cancer Cells and Metastasis (6 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Meng‐Feng Tsai collaborates with scholars based in Taiwan, United States and China. Meng‐Feng Tsai's co-authors include Pan‐Chyr Yang, Jin‐Yuan Shih, James Chih‐Hsin Yang, Shang‐Gin Wu, Chong‐Jen Yu, Yih‐Leong Chang, Jeremy J.W. Chen, Tzu‐Hua Chang, Pei‐Li Yao and Yinan Liu and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Meng‐Feng Tsai

55 papers receiving 1.9k citations

Peers

Meng‐Feng Tsai
Humam Kadara United States
Jiansong Ji China
Deepa S. Subramaniam United States
Weiheng Zhao China
Triparna Sen United States
Linping Xu China
He Ren China
Ximing Xu China
Xin Xu China
Delphine Mérino Australia
Humam Kadara United States
Meng‐Feng Tsai
Citations per year, relative to Meng‐Feng Tsai Meng‐Feng Tsai (= 1×) peers Humam Kadara

Countries citing papers authored by Meng‐Feng Tsai

Since Specialization
Citations

This map shows the geographic impact of Meng‐Feng Tsai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meng‐Feng Tsai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meng‐Feng Tsai more than expected).

Fields of papers citing papers by Meng‐Feng Tsai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meng‐Feng Tsai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meng‐Feng Tsai. The network helps show where Meng‐Feng Tsai may publish in the future.

Co-authorship network of co-authors of Meng‐Feng Tsai

This figure shows the co-authorship network connecting the top 25 collaborators of Meng‐Feng Tsai. A scholar is included among the top collaborators of Meng‐Feng Tsai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meng‐Feng Tsai. Meng‐Feng Tsai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Yi‐Ling, Yinan Liu, Yen‐Ting Lin, et al.. (2023). LncRNA SLCO4A1-AS1 suppresses lung cancer progression by sequestering the TOX4-NTSR1 signaling axis. Journal of Biomedical Science. 30(1). 80–80. 14 indexed citations
2.
Wu, Shang‐Gin, Tzu‐Hua Chang, Meng‐Feng Tsai, et al.. (2023). miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44. Molecular Therapy — Nucleic Acids. 35(1). 102091–102091. 12 indexed citations
3.
Wu, Shang‐Gin, et al.. (2023). Different treatment efficacies and T790M acquisition of EGFR‐TKIs on NSCLC patients with variable Del‐19 subtypes of EGFR. International Journal of Cancer. 153(2). 352–363. 4 indexed citations
4.
Tsai, Tzu‐Hsiu, Chien‐Hung Gow, Meng‐Feng Tsai, et al.. (2023). MiR‐503 pleiotropically regulates epithelial‐mesenchymal transition and targets PTK7 to control lung cancer metastasis. Cancer Medicine. 12(13). 14511–14525. 6 indexed citations
5.
Liu, Yinan, Meng‐Feng Tsai, Shang‐Gin Wu, Tzu‐Hua Chang, & Jin‐Yuan Shih. (2023). CD44s and CD44v8-10 isoforms confer acquired resistance to osimertinib by activating the ErbB3/STAT3 signaling pathway. Life Sciences. 336. 122345–122345. 6 indexed citations
6.
Liu, Yinan, Meng‐Feng Tsai, Shang‐Gin Wu, et al.. (2020). miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway. Molecular Therapy — Nucleic Acids. 22. 471–483. 38 indexed citations
7.
Gow, Chien‐Hung, Yinan Liu, Min‐Shu Hsieh, et al.. (2018). Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer. Neoplasia. 20(8). 838–847. 27 indexed citations
8.
Tsai, Meng‐Feng, et al.. (2015). Investigating the Influence of Anti-Cancer Drugs on the Mechanics of Cells Using AFM. BioNanoScience. 5(3). 156–161. 16 indexed citations
9.
Chen, Yen‐Fu, Min‐Shu Hsieh, Shang‐Gin Wu, et al.. (2014). Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations. Journal of Thoracic Oncology. 9(8). 1171–1179. 66 indexed citations
10.
Tsai, Meng‐Feng. (2014). Tumour suppressor HLJ1: A potential diagnostic, preventive and therapeutic target in non-small cell lung cancer. World Journal of Clinical Oncology. 5(5). 865–865. 20 indexed citations
11.
Tsai, Meng‐Feng, et al.. (2013). α-Synuclein and β-synuclein enhance secretion protein production in baculovirus expression vector system. Applied Microbiology and Biotechnology. 97(9). 3875–3884. 2 indexed citations
12.
Wu, Shang‐Gin, Chong‐Jen Yu, Meng‐Feng Tsai, et al.. (2012). Survival of lung adenocarcinoma patients with malignant pleural effusion. European Respiratory Journal. 41(6). 1409–1418. 79 indexed citations
13.
Huang, Cheng-Po, Meng‐Feng Tsai, Tzu‐Hua Chang, et al.. (2012). ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Letters. 328(1). 144–151. 129 indexed citations
14.
Tsai, Tzu‐Hsiu, Shang‐Gin Wu, Yih‐Leong Chang, et al.. (2012). Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma. Journal of Thoracic Oncology. 7(6). 993–1000. 31 indexed citations
15.
Wu, Shang‐Gin, Yao-Wen Kuo, Yih‐Leong Chang, et al.. (2011). EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR. Journal of Thoracic Oncology. 7(1). 98–104. 80 indexed citations
16.
Wu, Shang‐Gin, Yih‐Leong Chang, Jou‐Wei Lin, et al.. (2011). Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction. PLoS ONE. 6(8). e23303–e23303. 43 indexed citations
17.
Huang, Chun‐Ta, Ruoh‐Fang Yen, Mei‐Fang Cheng, et al.. (2009). Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Medical Oncology. 27(1). 9–15. 57 indexed citations
18.
Chen, Huei‐Wen, Jen‐Yi Lee, Jiying Huang, et al.. (2008). Curcumin Inhibits Lung Cancer Cell Invasion and Metastasis through the Tumor Suppressor HLJ1. Cancer Research. 68(18). 7428–7438. 189 indexed citations
19.
Yao, Pei‐Li, Meng‐Feng Tsai, Yi‐Chen Lin, et al.. (2005). Global expression profiling of theophylline response genes in macrophages: evidence of airway anti-inflammatory regulation. Respiratory Research. 6(1). 89–89. 22 indexed citations
20.
Yu, Hon‐Tsen, Kate Ching‐Ju Lin, Chiu-Jung Huang, et al.. (2001). Cloning, Characterization, and Phylogenetic Analysis of a Shrimp White Spot Syndrome Virus Gene That Encodes a Protein Kinase. Virology. 289(2). 362–377. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Humam Kadara Breakdown of academic impact, for papers by Jiansong Ji Breakdown of academic impact, for papers by Deepa S. Subramaniam Breakdown of academic impact, for papers by Weiheng Zhao Breakdown of academic impact, for papers by Triparna Sen Breakdown of academic impact, for papers by Linping Xu Breakdown of academic impact, for papers by He Ren Breakdown of academic impact, for papers by Ximing Xu Breakdown of academic impact, for papers by Xin Xu Breakdown of academic impact, for papers by Delphine Mérino
Rankless by CCL
2026